MACIR and adenocarcinoma: CCNH-C5orf30 was more frequent in lung cancer adenocarcinomas versus squamous type (67.7% versus 34.8%, p = 0.001) and colon cancer at advanced stages at the time of diagnosis (52.3% versus 18.8%, p = 0.037).